AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28627929 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced test, link-to-care, plus treat approach (TLC-Plus)
Number of subjects: 76
Study 28627929 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial incentives to increase linkage to care
Number of subjects: 76
Study 28627929 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial incentives to increase viral suppression
Number of subjects: 76
Study 28627929 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-delivered intervention to decrease risk behavior
Number of subjects: 76
Study 28627929 — intervention group
Group type: EXPERIMENTAL
Intervention: Provider and patient surveys
Number of subjects: 76
Study 26535951 — intervention group
Group type: EXPERIMENTAL
Intervention: Child-Parent Psychotherapy (CPP)
Number of subjects: 44
Study 26535951 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational Parenting Intervention (PPI)
Number of subjects: 44
Study 26535951 — intervention group
Group type: COMPARATOR
Intervention: Standard Community Services (Control)
Number of subjects: 44
Study 26535951 — intervention group
Group type: COMPARATOR
Intervention: Nonmaltreating Mothers (Comparison Group)
Number of subjects: 44
Study 23551511 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.3% sodium hypochlorite (NaOCl)
Number of subjects: 90
Study 23551511 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine (CHX)
Number of subjects: 90
Study 23551511 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetraclean
Number of subjects: 90
Study 23551511 — intervention group
Group type: EXPERIMENTAL
Intervention: MTAD
Number of subjects: 90
Study 23551511 — intervention group
Group type: COMPARATOR
Intervention: Positive control
Number of subjects: 90
Study 23551511 — intervention group
Group type: COMPARATOR
Intervention: Negative control
Number of subjects: 90
Study 21915441 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial coherence interferometry (PCI)
Number of subjects: 120
Study 21915441 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound (US)
Number of subjects: 120
Study 19794082 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorinostat (400 mg daily for 21 days) in arm A
Number of subjects: 37
Study 19794082 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorinostat (200 mg three times daily for 14 days followed by 1 week rest) in arm B
Number of subjects: 37
Study 17535940 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumer-assisted case management
Number of subjects: 203
Study 17535940 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-consumer-assisted case management
Number of subjects: 203
Study 17535940 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard clinic-based care
Number of subjects: 203
Study 15547458 — intervention group
Group type: EXPERIMENTAL
Intervention: naltrexone 50 mg daily plus usual program treatment
Number of subjects: 145
Study 15547458 — intervention group
Group type: COMPARATOR
Intervention: placebo plus usual treatment
Number of subjects: 145
Study 15547458 — intervention group
Group type: COMPARATOR
Intervention: usual treatment alone
Number of subjects: 145
Study 11707839 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate-based chemotherapy
Number of subjects: 0
Study 11707839 — intervention group
Group type: COMPARATOR
Intervention: Whole-brain radiation therapy (WBRT)
Number of subjects: 0
Study 9000657 — intervention group
Group type: EXPERIMENTAL
Intervention: HAT 0.5 mg/kg/week (n=4)
Number of subjects: 12
Study 9000657 — intervention group
Group type: EXPERIMENTAL
Intervention: HAT 1 mg/kg/week (n=2)
Number of subjects: 12
Study 9000657 — intervention group
Group type: EXPERIMENTAL
Intervention: HAT 0.5 mg/kg every other week (n=3)
Number of subjects: 12
Study 9000657 — intervention group
Group type: EXPERIMENTAL
Intervention: HAT 1 mg/kg every other week (n=3)
Number of subjects: 12
Study 9000657 — intervention group
Group type: COMPARATOR
Intervention: Historical controls (n=17)
Number of subjects: 12
Study 8272759 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid lowering programme
Number of subjects: 37
Study 8272759 — intervention group
Group type: EXPERIMENTAL
Intervention: Different inclusion criteria for treatment
Number of subjects: 37
Study 3548336 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic trisodium citrate anticoagulation
Number of subjects: 45
Study 3548336 — intervention group
Group type: COMPARATOR
Intervention: Low-dose controlled heparin anticoagulation
Number of subjects: 45
Study 30541572 — intervention group
Group type: EXPERIMENTAL
Intervention: Proprietary spearmint extract (PSE) 900 mg daily for 90 days
Number of subjects: 142
Study 30541572 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 142
Study 27184721 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus bevacizumab (CT+bevacizumab)
Number of subjects: 298
Study 27184721 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone (CT)
Number of subjects: 298
Study 24554040 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP
Number of subjects: 197
Study 24554040 — intervention group
Group type: COMPARATOR
Intervention: Routine
Number of subjects: 197
Study 22391670 — intervention group
Group type: EXPERIMENTAL
Intervention: Nerve stimulation (NS) alone in Group A
Number of subjects: 60
Study 22391670 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound guidance combined with nerve stimulation in Group B
Number of subjects: 60
Study 21092506 — intervention group
Group type: COMPARATOR
Intervention: Conventional dialysate (CD)
Number of subjects: 80
Study 21092506 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrapure dialysate (UPD)
Number of subjects: 80
Study 18273539 — intervention group
Group type: EXPERIMENTAL
Intervention: SE stents with low-pressure dilatation <12 atm (n = 143)
Number of subjects: 254
Study 18273539 — intervention group
Group type: COMPARATOR
Intervention: Conventional BE stents (n = 136)
Number of subjects: 254
Study 18273539 — intervention group
Group type: EXPERIMENTAL
Intervention: SE stents with low-pressure dilatation <12 atm
Number of subjects: 254
Study 18273539 — intervention group
Group type: COMPARATOR
Intervention: Conventional BE stents
Number of subjects: 254
Study 15842446 — intervention group
Group type: EXPERIMENTAL
Intervention: Early discharge with nurse follow-up (weekly or biweekly telephone calls)
Number of subjects: 101
Study 12974145 — intervention group
Group type: EXPERIMENTAL
Intervention: Lispro insulin and metformin
Number of subjects: 87
Study 12974145 — intervention group
Group type: EXPERIMENTAL
Intervention: Glimepiride and metformin combination
Number of subjects: 87
Study 12974145 — intervention group
Group type: EXPERIMENTAL
Intervention: Two daily doses of biphasic insulin 30/70 with bedtime NPH insulin
Number of subjects: 87
Study 12974145 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihyperglycemic metformin and insulin lispro therapy
Number of subjects: 87
Study 11361162 — intervention group
Group type: EXPERIMENTAL
Intervention: Stapled gastric bypass
Number of subjects: 50
Study 11361162 — intervention group
Group type: COMPARATOR
Intervention: Transected gastric bypass
Number of subjects: 50
Study 11361162 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study 9183237 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin lispro
Number of subjects: 722
Study 9183237 — intervention group
Group type: COMPARATOR
Intervention: Human regular insulin
Number of subjects: 722
Study 1534044 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (5 or 10 mg/day od)
Number of subjects: 40
Study 1534044 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine s.r. (20 or 40 mg BID)
Number of subjects: 40
Study 3956558 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/kg of pethidine im
Number of subjects: 21
Study 3956558 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of extradural pethidine
Number of subjects: 21
Study 3956558 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg of extradural pethidine
Number of subjects: 21
Study 3956558 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 21
Study 30703197 — intervention group
Group type: EXPERIMENTAL
Intervention: Ready-made spectacles
Number of subjects: 460
Study 30703197 — intervention group
Group type: COMPARATOR
Intervention: Custom-made spectacles
Number of subjects: 460
Study 28325070 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate
Number of subjects: 84
Study 28325070 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 26567010 — intervention group
Group type: EXPERIMENTAL
Intervention: Eribulin (1.4 mg/m² intravenously on days 1 and 8)
Number of subjects: 1062
Study 26567010 — intervention group
Group type: COMPARATOR
Intervention: Capecitabine (1.25 g/m² orally twice daily on days 1‐14)
Number of subjects: 1062
Study 26567010 — intervention group
Group type: COMPARATOR
Intervention: Capecitabine
Number of subjects: 1062
Study 26567010 — intervention group
Group type: EXPERIMENTAL
Intervention: Eribulin
Number of subjects: 1062
Study 26567010 — intervention group
Group type: EXPERIMENTAL
Intervention: Eribulin and Capecitabine
Number of subjects: 1062
Study 23895319 — intervention group
Group type: EXPERIMENTAL
Intervention: Rate-focused repeated readings (RR) intervention
Number of subjects: 76
Study 23895319 — intervention group
Group type: EXPERIMENTAL
Intervention: Prosody-focused repeated readings (RR) intervention
Number of subjects: 76
Study 21736003 — intervention group
Group type: EXPERIMENTAL
Intervention: Med‐Food Anticancer Program (MFAP)
Number of subjects: 80
Study 21736003 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study 20137477 — intervention group
Group type: EXPERIMENTAL
Intervention: rhPTH (1-34) 20 microg daily
Number of subjects: 205
Study 20137477 — intervention group
Group type: COMPARATOR
Intervention: elcatonin 20 U weekly
Number of subjects: 205
Study 20137477 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 205
Study 16703579 — intervention group
Group type: EXPERIMENTAL
Intervention: Aztreonam lysinate for inhalation (AI) 75 mg
Number of subjects: 24
Study 16703579 — intervention group
Group type: EXPERIMENTAL
Intervention: Aztreonam lysinate for inhalation (AI) 150 mg
Number of subjects: 24
Study 16703579 — intervention group
Group type: EXPERIMENTAL
Intervention: Aztreonam lysinate for inhalation (AI) 225 mg
Number of subjects: 24
Study 16703579 — intervention group
Group type: EXPERIMENTAL
Intervention: Aztreonam lysinate for inhalation (AI) 75 mg (adolescents)
Number of subjects: 24
Study 16703579 — intervention group
Group type: EXPERIMENTAL
Intervention: Aztreonam lysinate for inhalation (AI) 150 mg (adolescents)
Number of subjects: 24
Study 16703579 — intervention group
Group type: EXPERIMENTAL
Intervention: Aztreonam lysinate for inhalation (AI) 225 mg (adolescents)
Number of subjects: 24
Study 16703579 — intervention group
Group type: EXPERIMENTAL
Intervention: Aztreonam lysinate for inhalation (AI) 75 mg (adults)
Number of subjects: 24
Study 16703579 — intervention group
Group type: EXPERIMENTAL
Intervention: Aztreonam lysinate for inhalation (AI)
Number of subjects: 24
Study 16703579 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 15571779 — intervention group
Group type: EXPERIMENTAL
Intervention: HPLC method for determination of total pentosidine concentration in plasma
Number of subjects: 0
Study 11878737 — intervention group
Group type: EXPERIMENTAL
Intervention: PCEA plus night-time infusion
Number of subjects: 0
Study 11878737 — intervention group
Group type: COMPARATOR
Intervention: PCEA alone
Number of subjects: 0
Study 9777544 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical spine lateral glide oscillatory manipulation
Number of subjects: 24
Study 9777544 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 9777544 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 24
Study 7828356 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 micrograms TRH
Number of subjects: 80
Study 7828356 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 2893761 — intervention group
Group type: EXPERIMENTAL
Intervention: cimetidine 800 mg
Number of subjects: 30
Study 2893761 — intervention group
Group type: EXPERIMENTAL
Intervention: ranitidine 300 mg
Number of subjects: 30
Study 2893761 — intervention group
Group type: EXPERIMENTAL
Intervention: famotidine 40 mg
Number of subjects: 30
Study 2893761 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 30
Study 1810321 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluma Dentin Bond (two 30‐second applications)
Number of subjects: 20
Study 1810321 — intervention group
Group type: COMPARATOR
Intervention: Sterile water (control)
Number of subjects: 20
Study 823586 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg chlordiazepoxide
Number of subjects: 90
Study 823586 — intervention group
Group type: COMPARATOR
Intervention: Control condition (placebo)
Number of subjects: 90
Study 31281076 — intervention group
Group type: EXPERIMENTAL
Intervention: High-load resistance training (n=14)
Number of subjects: 45
Study 31281076 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-load resistance training (n=15)
Number of subjects: 45
Study 31281076 — intervention group
Group type: COMPARATOR
Intervention: Non-exercising control (n=16)
Number of subjects: 45
Study 28801392 — intervention group
Group type: EXPERIMENTAL
Intervention: Care package to increase women's awareness of the need for prompt reporting of RFM and standardized management to identify fetal compromise with timely delivery.
Number of subjects: 0
Study 26408873 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin plus glimepiride (3mg once daily)
Number of subjects: 180
Study 26408873 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin plus gliclazide (80 mg once daily)
Number of subjects: 180
Study 26408873 — intervention group
Group type: COMPARATOR
Intervention: Metformin (500 mg twice daily)
Number of subjects: 180
Study 23132548 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 794
Study 23132548 — intervention group
Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 794
Study 23132548 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative conversions to open surgery
Number of subjects: 794
Study 23132548 — intervention group
Group type: EXPERIMENTAL
Intervention: Right colonic cancers
Number of subjects: 794
Study 21645895 — intervention group
Group type: EXPERIMENTAL
Intervention: drospirenone (DRSP) 2 mg + E(2) 1 mg
Number of subjects: 90
Study 21645895 — intervention group
Group type: EXPERIMENTAL
Intervention: norethisterone acetate (NETA) 0.5 mg + E(2) 1 mg
Number of subjects: 90
Study 21645895 — intervention group
Group type: EXPERIMENTAL
Intervention: ethinilestradiol (EE) 0.020 mg + DRSP 3 mg
Number of subjects: 90
Study 21645895 — intervention group
Group type: EXPERIMENTAL
Intervention: ethinilestradiol (EE) 0.020 mg + desogestrel 0.15 mg
Number of subjects: 90
Study 21645895 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated postmenopausal and premenopausal women)
Number of subjects: 90
Study 19426396 — intervention group
Group type: EXPERIMENTAL
Intervention: lamivudine 100 mg daily
Number of subjects: 429
Study 19426396 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 429
Study 16434264 — intervention group
Group type: EXPERIMENTAL
Intervention: Pexelizumab
Number of subjects: 218
Study 16434264 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 218
Study 15296810 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-duration exclusive breast-feeding with Nevirapine (NVP) and intensive counseling; abrupt cessation of breast-feeding at 4 months.
Number of subjects: 1200
Study 15296810 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive and frequent clinic- and home-based counseling to support exclusive breast-feeding.
Number of subjects: 1200
Study 11305288 — intervention group
Group type: EXPERIMENTAL
Intervention: General health quality of life measure
Number of subjects: 279
Study 11305288 — intervention group
Group type: EXPERIMENTAL
Intervention: CMV retinitis-specific quality of life measure
Number of subjects: 279
Study 11305288 — intervention group
Group type: EXPERIMENTAL
Intervention: General health perceptions and energy scales
Number of subjects: 279
Study 9732194 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg piroxicam (2 ml) administered intramuscularly 45 min before ESWL
Number of subjects: 60
Study 9732194 — intervention group
Group type: COMPARATOR
Intervention: Saline (2 ml) administered intramuscularly 45 min before ESWL
Number of subjects: 60
Study 8053882 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler ultrasound assessment of umbilical artery waveform indices in high risk fetuses
Number of subjects: 0
Study 8053882 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler assessment of middle cerebral and aortic vessels in high risk fetuses
Number of subjects: 0
Study 8053882 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler ultrasound assessment of umbilical and uteroplacental vasculatures
Number of subjects: 0
Study 8053882 — intervention group
Group type: EXPERIMENTAL
Intervention: Umbilical artery waveform indices in low risk fetuses
Number of subjects: 0
Study 8053882 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler waveform indices of middle cerebral and aortic vessels
Number of subjects: 0
Study 8053882 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler ultrasound
Number of subjects: 0
Study 3281462 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotetan every 12 hours
Number of subjects: 287
Study 3281462 — intervention group
Group type: COMPARATOR
Intervention: Cefoxitin every 6 or 8 hours
Number of subjects: 287
Study 31957953 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose TAS-205 (6.67-13.33 mg/kg/dose)
Number of subjects: 36
Study 31957953 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose TAS-205 (13.33-26.67 mg/kg/dose)
Number of subjects: 36
Study 31957953 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 26253149 — intervention group
Group type: EXPERIMENTAL
Intervention: Organizational, time management, and planning (OTMP) skills training intervention
Number of subjects: 37
Study 26253149 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (no intervention)
Number of subjects: 37
Study 28274234 — intervention group
Group type: EXPERIMENTAL
Intervention: Sapropterin (10 mg/kg/day) plus phenylalanine-restricted diet
Number of subjects: 56
Study 28274234 — intervention group
Group type: COMPARATOR
Intervention: Phenylalanine-restricted diet only
Number of subjects: 56
Study 26278126 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral truncal ligation (BTL) of the inferior thyroid artery
Number of subjects: 83
Study 26278126 — intervention group
Group type: COMPARATOR
Intervention: Non-BTL
Number of subjects: 83
Study 23742620 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurasidone
Number of subjects: 0
Study 23742620 — intervention group
Group type: COMPARATOR
Intervention: Quetiapine XR
Number of subjects: 0
Study 21419010 — intervention group
Group type: COMPARATOR
Intervention: Local anesthetics without buprenorphine (A group)
Number of subjects: 60
Study 21419010 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthetics plus 2 µg/kg buprenorphine (B group)
Number of subjects: 60
Study 21419010 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular injection 2 µg/kg buprenorphine before anesthesia (C group)
Number of subjects: 60
Study 18665787 — intervention group
Group type: EXPERIMENTAL
Intervention: Bazedoxifene 20 mg/d
Number of subjects: 6847
Study 18665787 — intervention group
Group type: EXPERIMENTAL
Intervention: Bazedoxifene 40 mg/d
Number of subjects: 6847
Study 18665787 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/d
Number of subjects: 6847
Study 18665787 — intervention group
Group type: EXPERIMENTAL
Intervention: Bazedoxifene 20 mg/d (in higher fracture risk subgroup)
Number of subjects: 6847
Study 17186182 — intervention group
Group type: EXPERIMENTAL
Intervention: lafutidine (10 mg, twice daily for 12 weeks)
Number of subjects: 80
Study 17186182 — intervention group
Group type: COMPARATOR
Intervention: famotidine (20 mg, twice daily for 12 weeks)
Number of subjects: 80
Study 12679422 — intervention group
Group type: EXPERIMENTAL
Intervention: GH replacement therapy (9.6 micro g/kg body weight.d)
Number of subjects: 19
Study 11592235 — intervention group
Group type: EXPERIMENTAL
Intervention: Subclavicular route
Number of subjects: 100
Study 11592235 — intervention group
Group type: COMPARATOR
Intervention: Supraclavicular route
Number of subjects: 100
Study 9741862 — intervention group
Group type: EXPERIMENTAL
Intervention: Prospective randomized effectiveness studies
Number of subjects: 804
Study 9741862 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomization
Number of subjects: 804
Study 9741862 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial findings from two studies
Number of subjects: 804
Study 8147520 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled midazolam sedation
Number of subjects: 30
Study 8147520 — intervention group
Group type: COMPARATOR
Intervention: Anaesthetist-controlled midazolam sedation
Number of subjects: 30
Study 3139019 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical mupirocin therapy
Number of subjects: 49
Study 3139019 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 31983237 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical proparacaine 0.5%
Number of subjects: 36
Study 31983237 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical proparacaine 0.5% (additional drop)
Number of subjects: 36
Study 31983237 — intervention group
Group type: COMPARATOR
Intervention: Topical proparacaine 0.5% and povidone iodine
Number of subjects: 36
Study 31983237 — intervention group
Group type: COMPARATOR
Intervention: Povidone iodine
Number of subjects: 36
Study 31983237 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient experience surveys
Number of subjects: 36
Study 30468730 — intervention group
Group type: EXPERIMENTAL
Intervention: PC gaming platform intervention for balance training
Number of subjects: 54
Study 30468730 — intervention group
Group type: COMPARATOR
Intervention: Control group using a computer mouse in standing position
Number of subjects: 54
Study 27860037 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-centred communication (PCC)
Number of subjects: 80
Study 27860037 — intervention group
Group type: EXPERIMENTAL
Intervention: Doctor-centred communication (DCC)
Number of subjects: 80